Fasikl has raised $27.0M in total across 1 funding round.
Fasikl's investors include Qiming Venture Partners.
Fasikl is a neuro-AI technology company that develops advanced AI-supported neural platforms aimed at transforming neurotherapies. Its flagship product, the Felix NeuroAI™ Wristband, is the first FDA-cleared, noninvasive AI therapeutic device for essential tremor, providing personalized, all-day tremor relief without drugs or surgery. Fasikl’s technology captures neural signals at an unprecedented resolution and uses AI to decode and modulate these signals, enabling therapies that improve motor control and manage neurological disorders. The company serves patients with neurological and movement disorders, including amputees and paralyzed individuals, addressing unmet needs in pain relief, prosthetic control, and functional restoration. Fasikl is experiencing strong growth momentum, validated by FDA breakthrough device designations and clinical trial success, with plans to expand its AI therapeutics portfolio across multiple indications[1][2][3][5].
Founded in 2019 as a spin-off from the University of Minnesota, Fasikl was established by Dr. Zhi Yang and his team, building on over 20 years of foundational research in neural signal decoding and AI therapeutics. The idea emerged from a vision to create a synergistic relationship between the brain and AI, inspired by the philosophical concept of “unity of knowledge and action,” which emphasizes harmonious interaction between awareness and control of the body. Early pivotal moments include the development of the Felix NeuroAI™ Wristband, which underwent rigorous double-blind, randomized clinical trials demonstrating significant improvements in essential tremor symptoms, and the receipt of FDA breakthrough device designations for their implantable neural platform. These milestones have positioned Fasikl as a pioneer in intelligent bioelectronic medicine[1][3][4].
Fasikl operates at the intersection of neurotechnology, artificial intelligence, and bioelectronic medicine, riding the trend toward intelligent, personalized therapies that integrate AI with human neural systems. The timing is critical as advances in AI, neural interfaces, and regulatory acceptance converge to enable new treatment paradigms beyond traditional pharmaceuticals and devices. Market forces such as increasing prevalence of neurological disorders, demand for noninvasive therapies, and growth in wearable health tech favor Fasikl’s approach. By pioneering AI-powered neural decoding and modulation, Fasikl influences the broader ecosystem by setting new standards for neurotherapeutics, enabling more effective, adaptive, and patient-centric treatments, and advancing brain-machine communication technologies[1][2][4].
Fasikl is poised to expand its footprint in neuro-AI therapeutics, leveraging its versatile platform to address a wider range of neurological and movement disorders. Future trends shaping its journey include the growing adoption of AI in personalized medicine, advances in neural interface hardware, and increasing integration of cloud-based AI for continuous therapy optimization. Fasikl’s influence is likely to evolve from niche neurotechnology to a foundational player in bioelectronic medicine, potentially transforming treatment paradigms for millions of patients worldwide. Continued innovation, regulatory milestones, and market expansion will be key to sustaining its leadership in this emerging field[1][3][5].
Fasikl has raised $27.0M across 1 funding round. Most recently, it raised $27.0M Series B in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $27.0M Series B | Qiming Venture Partners |
